Skip to content

UroGen Pharma URGN Business Segments

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Revenue by Product
Jelmyto$95.45M+3.9%$93.99M+4.0%$94.74M+6.0%$94.24M+10.9%$91.87M+9.0%
Zusduri$45.05M$15.8M$1.78M$0

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How does UroGen Pharma break its business down?
UroGen Pharma (URGN) reports revenue by product across 2 parts — Jelmyto and Zusduri. Each is extracted from the segment footnotes and tracked over time.
Where does UroGen Pharma's segment data come from?
Segment breakdowns are pulled from the segment footnotes in UroGen Pharma's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.